Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the growth of the markets for treatment of non- ST-elevation myocardial infarction (NSTEMI) and unstable angina, both of which are conditions of acute coronary syndrome, will be driven by an increase in the number of diagnosed events and revascularization procedures conducted to treat the indication.

"Key market drivers will include the increased use of Eli Lilly's ReoPro (abciximab) and The Medicines Company's Angiomax (bivalirudin) during percutaneous coronary interventions," said Ruth Brown, Ph.D., analyst at Decision Resources. "Angiomax has a short half-life, a favorable side-effect profile, and offers advantages over both unfractionated heparin and low- molecular-weight heparin in high-risk patients undergoing percutaneous coronary intervention. Another key driver is the increased use of Sanofi- Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) in all markets. Impressive clinical trial evidence now supports the use of dual antiplatelet therapy-aspirin plus clopidogrel-to treat acute coronary syndrome patients."

The new Pharmacor study, entitled Acute Coronary Syndrome: NSTEMI, also finds that the introduction of novel agents that address several unmet needs will also drive growth, although overall market value will be constrained by the patent expiries of popular agents from several key drug classes.

About Acute Coronary Syndrome

Coronary artery disease is the leading cause of death in the Western world. Unstable angina and non-ST-elevation myocardial infarction, both of which are conditions of acute coronary syndrome, are among the most frequent clinical manifestations of coronary artery disease.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Legislation in The United States, Japan, and Europe Provides Financial Incentives to Biopharmaceutical Companies Producing Orphan Drugs

View Now